Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1

Leukemia

Volumn 29, Issue 2, 2015, Pages 433-440

  Fukuda, S ^a   Hoggatt, J ^b,c   Singh, P ^b   Abe, M ^a   Speth, J M ^b   Hu, P ^b   Conway, E M ^d   Nucifora, G ^e   Yamaguchi, S ^a   Pelus, L M ^b  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Harvard University   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EVI 1 TRANSCRIPTION FACTOR; PROTEIN; SALL2 PROTEIN; SURVIVIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG; BIRC5 PROTEIN, MOUSE; DNA BINDING PROTEIN; EVI1 PROTEIN, MOUSE; GATA2 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MECOM PROTEIN, HUMAN; PBX1 PROTEIN, MOUSE; REPRESSOR PROTEIN; SALL2 PROTEIN, MOUSE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL CYCLE; CELL DIVISION; CELL LOSS; CELL PROLIFERATION; CHIMERA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE DELETION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; THROMBOCYTE COUNT; ALLELE; ANIMAL; C57BL MOUSE; CYTOLOGY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PHENOTYPE; PROTO ONCOGENE; RETROVIRIDAE;

ALLELES; ANIMALS; BONE MARROW CELLS; CELL CYCLE; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GATA2 TRANSCRIPTION FACTOR; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROTO-ONCOGENES; REPRESSOR PROTEINS; RETROVIRIDAE; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84940238192     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.183     Document Type: Article

References (50)

1. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
2. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
3. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-1098.
4. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001; 97: 2784-2790.
5. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196-203.
6. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387-388.
7. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 2002; 100: 2463-2471.
8. Fukuda S, Mantel CR, Pelus LM. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 2004; 103: 120-127.
9. Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004; 199: 69-80.
10. Song J, So T, Cheng M, Tang X, Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005; 22: 621-631.
11. Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 2004; 199: 399-410.
12. Altznauer F, Martinelli S, Yousefi S, Thurig C, Schmid I, Conway EM et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 2004; 199: 1343-1354.
13. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci USA 2005; 102: 11480-11485.
14. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683-2692.
15. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158: 1757-1765.
16. Fukuda S, Singh P, Moh A, Abe M, Conway EM, Boswell HS et al. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood 2009; 114: 394-403.
17. Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 2007; 204 : 1603-1611.
18. Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/ CXCL2delta4. Blood 2004; 103: 110-119.
19. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004; 114: 713-719.
20. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
21. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007; 2: 2366-2382.
22. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001; 98: 2091-2100.
23. Fukuda S, Pelus LM. Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle 2002; 1: 322-326.
24. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 2000; 95: 1435-1442.
25. Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA 2005; 102: 9194-9199.
26. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002; 298: 601-604.
27. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371: 221-226.
28. Rodrigues NP, Janzen V, Forkert R, Dombkowski DM, Boyd AS, Orkin SH et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood 2005; 106: 477-484.
29. Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y et al. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene 2009; 28: 4364-4374.
30. Ficara F, Murphy MJ, Lin M, Cleary ML. Pbx1 regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence. Cell Stem Cell 2008; 2: 484-496.
31. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008; 3: 207-220.
32. Chai L. The role of HSAL (SALL) genes in proliferation and differentiation in normal hematopoiesis and leukemogenesis. Transfusion 2011; 51(Suppl 4): 87S-93S.
33. Berry FB, O'Neill MA, Coca-Prados M, Walter MA. FOXC1 transcriptional regulatory activity is impaired by PBX1 in a filamin A-mediated manner. Mol Cell Biol 2005; 25: 1415-1424.
34. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, Wiltshire T et al. Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet 2005; 37: 225-232.
35. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011; 333: 218-221.
36. Kostrouchova M, Kostrouch Z, Saudek V, Piatigorsky J, JE Rall. BIR-1, a Caenorhabditis elegans homologue of Survivin, regulates transcription and development. Proc Natl Acad Sci USA 2003; 100: 5240-5245.
37. Asanuma K, Tsuji N, Endoh T, Yagihashi A, Watanabe N. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol 2004; 172: 3922-3929.
38. Takizawa BT, Uchio EM, Cohen JJ, Wheeler MA, Weiss RM. Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. Cancer Invest 2007; 25: 678-684.
39. Balkhi MY, Christopeit M, Chen Y, Geletu M, Behre G. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp Hematol 2008; 36: 1449-1460.
40. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med 2011; 208: 2403-2416.
41. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10: 1319-1328.
42. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011; 117: 3617-3628.
43. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR et al. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012; 120: 173-180.
44. Persons DA, Allay JA, Allay ER, Ashmun RA, Orlic D, Jane SM et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood 1999; 93 : 488-499.
45. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010; 430: 199-205.
46. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res 2005; 65: 3531-3534.
47. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983; 131: 1300-1305.
48. Pelus LM, Ottmann OG, Nocka KH. Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-alpha, -beta, and -gamma and an effect mediated by tumor necrosis factor. J Immunol 1988; 140: 479-484.
49. Magee WE, Griffith MJ. The liver as a site for interferon production in response to poly I:poly C. Life Sci II 1972; 11: 1081-1086.
50. Manetti R, Annunziato F, Tomasevic L, Gianno V, Parronchi P, Romagnani S et al. Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-alpha and interleukin-12. Eur J Immunol 1995; 25: 2656-2660.